US FDA grants fast track designation to Clarity Pharma’s Cu-64 SAR-bisPSMA in biochemical recurrence of prostate cancer: Sydney, Australia Monday, January 27, 2025, 14:00 Hrs [I ...
Some results have been hidden because they may be inaccessible to you